Clinical trials: Amyloid Beta-protein
Alzheimer Disease, Alzheimer Disease (AD)
DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau
This Phase 1 study will test the safety and immune response of the investigational vaccine DUVAX in healthy adults. Participants will be randomly assigned to receive either DUVAX or placebo by intramuscular injection.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Preclinical Alzheimer's Disease
- Trial name
- DU-PRISM (NCT07142278)
- Testing
- DUVAX 200 µg, DUVAX 400 µg
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Alzheimer Disease
Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's Disease
This is a multi-center, Phase 1b, randomized, double-blind, placebo-controlled parallel-group trial in adults with mild to moderate AD.
- Trial name
- NCT03522129
- Testing
- CT1812
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Cognition Therapeutics
Mild Cognitive Impairment
Home-based Cognitive Monitoring in MCI
This study is an observational study to confirm usefulness of a home-based cognitive monitoring in non-demented patients with high-risk of dementia
- Trial name
- NCT04350801
- Testing
- home-based cognitive monitoring
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Prostate Cancer
Predicting Cognitive Decline From Androgen Deprivation Therapy
Androgen Deprivation Therapy (ADT) is associated with cognitive impairment and dementia in men with prostate cancer. Pre-clinical data suggest that ADT-induced hypogonadism leads to accumulation of beta-amyloid plaques in the…
- Trial name
- ABC (NCT05820932)
- Testing
- Blood-based assay, Cognitive assessments, Quality of Life Surveys
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of California, San Francisco
Alzheimer, Alzheimer Dementia (AD)
Restoring Cervical Lymphatic Drainage in Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative disorder associated with the accumulation of abnormal proteins, including amyloid-beta and tau, in the brain.
- Trial name
- LymphDAD (NCT07854327)
- Testing
- Cervical lymphovenous anastomosis (LVA)
- Where
- Italy
- Volunteers
- 5 people
- Sponsor
- University of Siena
Alzheimer Disease
Clinical Trial to Explore the the Amyloid Beta Draining Effect of Thiethylperazine (TEP) in Subjects With Newly Diagnosed Early-to-mild Dementia Due to Alzheimer's Disease (AD) in Comparison to Healthy Volunteers
This proof-of-mechanism clinical trial study will test the efficacy and safety of thiethylperazine (TEP) in subjects with early onset of Alzheimer's Disease (AD).
- Trial name
- drainAD (NCT03417986)
- Testing
- TEP
- Where
- 2 sites in Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Immungenetics AG
Parkinson Disease, Neurological Disorders
Amyloid Beta and Cognition in Parkinson Disease
The investigators propose to study persons with Parkinson Disease (PD) with detailed clinical, cognitive and imaging at the time of study entry and repeat these assessments 2 years later.
- Trial name
- NCT01754168
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Michigan
Sleep, Alzheimer Disease
Sleep Trial to Prevent Alzheimer's Disease
The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.
- Trial name
- SToP-AD (NCT04629547)
- Testing
- Suvorexant 20 mg
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Bioavailability, Gut Microbiome
Curcumin and Retinal Study
To test how two weeks of curcumin supplementation would cross the blood brain barrier (BBB) and attach to amyloid beta proteins, to assess the feasibility (safety and bioavailability), and to explore the resulting…
- Conditions
- Bioavailability, Gut Microbiome, Safety
- Trial name
- NCT05774704
- Testing
- Low curcumin group, High curcumin group
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Texas Tech University Health Sciences Center
Alzheimer's Disease
Observational Study to Monitor Long-term Immunogenicity and Efficacy of UB 311 Vaccine in Subjects With Alzheimer's Disease
The purpose of this observational study is to determine whether the vaccine (UB 311), targeting the N-terminal amino acids (1-14) of the amyloid beta peptide, has long-term immunogenicity and efficacy in individuals diagnosed…
- Trial name
- NCT01189084
- Testing
- Observational
- Where
- 2 sites in Taiwan
- Volunteers
- 14 people
- Sponsor
- United Biomedical
Alzheimer's Disease (AD), Neurodegenerative Disease
A Biomarker-chip Assay in Preserved Red Blood Cells for the Diagnosis of Alzheimer's Disease
The ADCHIP study (ST0067) is a non-interventional, monocentric, prospective study conducted by Amoneta Diagnostics and the Leenaards Memory Center (Lausanne, Switzerland).
- Conditions
- Alzheimer's Disease (AD), Neurodegenerative Disease, Dementia, Frontotemporal Dementia (FTD)
- Trial name
- ADCHIP (NCT07307872)
- Where
- Switzerland
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Amoneta Diagnostics SAS
Alzheimer Disease
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
This research will look at how the brain may change in people with Alzheimer disease (AD). The purpose of this research is to find out whether changes in the brain in people with Alzheimer disease can be detected using a brain…
- Trial name
- MNI-558 (NCT01217021)
- Testing
- [18F] MNI-558
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Hypertension
Hypertension, Intracranial Pulsatility and Brain Amyloid-beta Accumulation in Older Adults (HIPAC Trial)
The aim of this study is to determine if lowering blood pressure using FDA approved medication (antihypertensive drugs) alters brain pulsatility and reduces brain amyloid beta protein accumulation in older adults.
- Trial name
- HIPAC (NCT03354143)
- Testing
- Standard Care, Intensive Treatment
- Where
- United States
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Alzheimer Disease
Magnetic Resonance Spectroscopy Study of Memantine in Alzheimer's Disease
We are studying subjects with mild to moderate Alzheimer's disease who have been on a stable dose of any cholinesterase inhibitor [donepezil (Aricept), rivastigmine (Exelon), or galantamine (Razadyne)] for at least 3 months, and…
- Trial name
- NCT00551161
- Testing
- memantine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwell Health
MILD COGNITIVE IMPAIRMENT
Identification of Biomarkers Sensitive to Disease Progression in Patients With Mild Cognitive Impairment
THE STUDY WILL BE A TWO-PART RESEARCH PART A and PART A extended: 1. To implement a "common" MRI acquisition protocol in multiple centers across Europe (Pharma-COG partners). 2.
- Trial name
- NCT01425957
- Testing
- Lumbar puncture
- Where
- 13 sites in France, Germany and 4 more
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Qualissima
Alzheimer Disease
Effects of Sleep Deprivation on Cerebrospinal Fluid (CSF) Amyloid-beta (Aβ) Dynamics
Introduction: Alzheimer's disease (AD) is characterized by neurodegeneration of the brain in the form of neurofibrillary tangles and plaques containing the amyloid-beta protein (Abeta).
- Trial name
- AWAKE (NCT01194713)
- Testing
- Sleep deprivation
- Where
- Netherlands
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University Medical Center Nijmegen
Alzheimers Disease
Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects
The underlying goal of this study is to assess 123-I MNI-187 SPECT imaging as a tool to detect ß-amyloid deposition in the brain of AD research participants and age- and gender-matched healthy subjects.
- Trial name
- NCT00456417
- Testing
- 123-I MNI-187 Injection and Imaging Procedures
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Institute for Neurodegenerative Disorders
Alzheimer Disease
Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology
To determine the sensitivity and specificity of the visual assessment of tracer uptake in the Florbetaben PET images compared to histological verification of the presence or absence of cerebral β-amyloid in the respective…
- Trial name
- NCT01020838
- Testing
- Florbetaben (BAY94-9172)
- Where
- 19 sites in United States, Australia and 3 more
- Volunteers
- 218 people
- Sponsor
- Lantheus Biosciences Ltd.
Alzheimer Disease, Dementia
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
This is a bridging study to visually and quantitatively assess PET images obtained after single application of 300 MBq [18F]florbetaben and PET scanning of patients with Alzheimer disease.
- Conditions
- Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases
- Trial name
- NCT05527288
- Testing
- Drug: [18F]florbetaben
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer Disease, Dementia
Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia
The 'Investigating the Impact of Alzheimer's Disease Diagnostics in British Columbia' (IMPACT-AD BC) study is an observational, longitudinal cohort study that will examine the impact of cerebrospinal fluid (CSF) testing for core…
- Conditions
- Alzheimer Disease, Dementia, Cognitive Impairment, Mild Cognitive Impairment
- Trial name
- IMPACT-AD BC (NCT05002699)
- Testing
- Alzheimer's disease CSF biomarkers
- Where
- 4 sites in Canada
- Volunteers
- 120 people
- Sponsor
- University of British Columbia